Poor
Non-Aligned
Patient Risk:
High
Summary
Multiple extracted claims are not supported by the provided FDA label sections (notably efficacy/outcomes, remission, remission/clinical effectiveness wording, and several adverse-effect assertions). Additionally, critical label areas (boxed warnings, contraindications, dosing/safety, pregnancy/pediatrics) were not provided for verification, increasing the likelihood of material nonalignment.
Category Scores
Accurate Statements
Keytruda (pembrolizumab) is a monoclonal antibody.
11 DESCRIPTION: 'Pembrolizumab is a ... monoclonal IgG4 kappa antibody.'
Keytruda targets the PD-1 protein on T-cells.
12.1 Mechanism of Action: 'PD-1 receptor found on T cells' and 'Pembrolizumab ... binds to the PD-1 receptor'.
Keytruda blocks the interaction of PD-1 with PD-L1.
12.1 Mechanism of Action: 'blocks its interaction with PD-L1 and PD-L2'.
Keytruda has been approved for treatment of melanoma and NSCLC.
1.1 Melanoma and 1.2 Non-Small Cell Lung Cancer indications.
Keytruda has been approved for treatment of head and neck cancer.
1.4 Head and Neck Squamous Cell Cancer indication.
Unsupported Statements
Keytruda can lead to complete remission in some cases.
No remission/complete remission statements in provided label sections.
Keytruda has been shown to be highly effective in the treatment of melanoma.
No effectiveness/higher-than-other language in provided label sections.
In a pivotal clinical trial in advanced melanoma, Keytruda demonstrated significant improvement in overall survival compared to chemotherapy.
No trial outcome comparison data in provided label sections.
In a pivotal clinical trial in advanced melanoma, Keytruda demonstrated significant improvement in progression-free survival compared to chemotherapy.
No trial outcome comparison data in provided label sections.
In a clinical trial in advanced NSCLC, Keytruda demonstrated significant improvement in overall survival compared to chemotherapy.
No trial outcome comparison data in provided label sections.
In a clinical trial in advanced NSCLC, Keytruda demonstrated significant improvement in progression-free survival compared to chemotherapy.
No trial outcome comparison data in provided label sections.
Common side effects of Keytruda include fatigue.
No adverse reaction frequency/listing for fatigue in provided label sections.
Keytruda can cause fatigue that can be severe in some cases.
No fatigue severity statements in provided label sections.
Keytruda can cause an itchy rash.
Provided label text mentions rash/dermatitis but does not state 'itchy'.
Common side effects of Keytruda include diarrhea.
Provided label text states immune-mediated colitis 'may present with diarrhea' but does not describe diarrhea as 'common'.
Keytruda can cause diarrhea that can be severe in some cases.
Provided label excerpt does not explicitly link 'diarrhea' severity to the claim wording.
According to DrugPatentWatch.com, the patent for Keytruda is set to expire in 2028.
Patent timing and third-party sources are not part of FDA-approved label sections provided.
The patent expiration of Keytruda may make generic versions available in the near future.
Generic availability predictions are not supported by FDA label sections provided.
Activated T-cells attack and kill cancer cells after Keytruda therapy.
Provided label mechanism supports immune inhibition removal/anti-tumor immune response but does not explicitly state 'attack and kill cancer cells after therapy'.
Keytruda can lead to tumor shrinkage.
Label supports decreased tumor growth in mouse models but does not explicitly use the clinical term 'tumor shrinkage'.
Contradictions
Important Omissions
Boxed warnings presence/contents.
Importance:
High
Contraindications.
Importance:
High
Dosage and administration (including dosing modifications, withholding/discontinuation rules tied to severity).
Importance:
High
Use in pregnancy/lactation and pregnancy risk statements.
Importance:
High
Pediatric use/safety statements (including age limitations, if any, tied to indications).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several extracted safety-related and efficacy-related statements are not supported by the provided label sections (including frequency/severity claims for fatigue/diarrhea and remission/clinical outcome comparisons). Additionally, major safety label components (boxed warnings/contraindications/dosing and population safety) were not provided for verification, limiting the ability to ensure label-aligned guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Non-Aligned
Primary Issue
Numerous claims are unsupported or only partially supported by the provided label excerpts, especially efficacy/outcome and adverse-effect frequency/severity statements; also critical label sections were not available to confirm safety/contraindications/dosing.
Suggested Improvement
Restrict claims to what is explicitly present in the provided FDA label sections (e.g., approved indications and the described mechanism/warnings). Remove or rephrase unsupported statements about remission, trial outcome superiority, and 'common' or 'severe' adverse effects unless the corresponding FDA label sections (adverse reactions table/BOXED WARNING/contraindications/dosing modifications) are supplied and support the wording.